@article{11fd6089473b494e8ae89e22961cbe23,
title = "A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies.",
author = "Piha-Paul, \{Sarina Anne\} and Alpesh Amin and Christina Kovacs and Andrea Magley and Purkayastha, \{D. Das\} and Ying Zhuo",
note = "TPS2616 Background: Spartalizumab is an immunoglobulin G4 humanized monoclonal antibody that binds with subnanomolar affinity to PD-1. LAG525 is an immunoglobulin G4 humanized monoclonal antibody that binds LAG-3 with low nanomolar affinity, inhibiting the LAG-3 interaction with MHC class II and potentially restoring the activity of antitumor effector cells and enhancing anti-PD-1 antitumor activity.",
year = "2018",
month = may,
day = "20",
doi = "10.1200/JCO.2018.36.15\_SUPPL.TPS2616",
language = "American English",
volume = "36",
journal = "Journal of Clinical Oncology",
}